Private sector investment in overall health research and development (R&D) exceeds $150 billion annually, but only $5.9 billion of this is focused on global health diseases that primarily affect low- and middle-income countries (LMICs). A recent EPAR review examines the evidence in the literature for five hypothesized disincentives to private sector investment in global health R&D, and looks at examples of policy incentives that may help promote private sector investment.
EPAR reviewed the literature on factors affecting private sector investment in global health R&D. Partnerships are common across all phases of preclinical and clinical research. Both within the private sector and spanning the private, public, and philanthropic sectors, partnerships are generally seen as effective mechanisms to overcome research disincentives and increase private investment in global health R&D.